Metastasis-inhibiting composition of novel methylsulfonamide derivative compound
US-2024025845-A1 · Jan 25, 2024 · US
Prmt1 inhibitors and uses thereof
US2017233347A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017233347-A1 |
| Application number | US-201615276324-A |
| Country | US |
| Kind code | A1 |
| Filing date | Sep 26, 2016 |
| Priority date | Mar 14, 2013 |
| Publication date | Aug 17, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
First claim
Opening claim text (preview).
1 .- 41 . (canceled) 142 . A compound that is or salt thereof. 143 . A pharmaceutical composition comprising a compound of claim 142 , or salt thereof, and a pharmaceutically acceptable carrier. 144 . A compound that is N-(4-(4-((methyl(2-(methylamino)ethyl)amino)methyl)-1H-pyrazol-3-yl)-2-(trifluoromethyl)phenyl)isobutyramide, or salt thereof. 145 . A pharmaceutical composition comprising a compound of claim 144 , or salt thereof, and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Drugs for immunological or allergic disorders · CPC title
Antineoplastic agents · CPC title
- C07D231/12Primary
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017233347A1 cover?
- Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
- Who is the assignee on this patent?
- Epizyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).